Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury
Jillian Strandberg, … , Lanlan Zhou, Wafik S. El-Deiry
Jillian Strandberg, … , Lanlan Zhou, Wafik S. El-Deiry
Published January 14, 2025
Citation Information: J Clin Invest. 2025;135(5):e173649. https://doi.org/10.1172/JCI173649.
View: Text | PDF
Research Article Oncology

TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury

  • Text
  • PDF
Abstract

Radiotherapy can be limited by pneumonitis, which is impacted by innate immunity, including pathways regulated by TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from toxic effects of radiation and found that 2 different agonists, parenteral PEGylated trimeric TRAIL (TLY012) and oral TRAIL-inducing compound (TIC10/ONC201), could reduce pneumonitis, alveolar wall thickness, and oxygen desaturation. Lung protection extended to late effects of radiation including less fibrosis at 22 weeks in TLY012-rescued survivors versus unrescued surviving irradiated mice. Wild-type orthotopic breast tumor–bearing mice receiving 20 Gy thoracic radiation were protected from pneumonitis with disappearance of tumors. At the molecular level, radioprotection appeared to be due to inhibition of CCL22, a macrophage-derived chemokine previously associated with radiation pneumonitis and pulmonary fibrosis. Treatment with anti-CCL22 reduced lung injury in vivo but less so than TLY012. Pneumonitis severity was worse in female versus male mice, and this was associated with increased expression of X-linked TLR7. Irradiated mice had reduced esophagitis characterized by reduced epithelial disruption and muscularis externa thickness following treatment with the ONC201 analog ONC212. The discovery that short-term treatment with TRAIL pathway agonists effectively rescues animals from pneumonitis, dermatitis, and esophagitis following high doses of thoracic radiation exposure has important translational implications.

Authors

Jillian Strandberg, Anna Louie, Seulki Lee, Marina Hahn, Praveen Srinivasan, Andrew George, Arielle De La Cruz, Leiqing Zhang, Liz Hernandez Borrero, Kelsey E. Huntington, Payton De La Cruz, Attila A. Seyhan, Paul P. Koffer, David E. Wazer, Thomas A. DiPetrillo, Stephanie L. Graff, Christopher G. Azzoli, Sharon I. Rounds, Andres J. Klein-Szanto, Fabio Tavora, Evgeny Yakirevich, Abbas E. Abbas, Lanlan Zhou, Wafik S. El-Deiry

×

Figure 7

Reduced severity of radiation esophagitis with ONC212 for 2 weeks after a toxic thoracic x-ray irradiation dose in mice.

Options: View larger image (or click on image) Download as PowerPoint
Reduced severity of radiation esophagitis with ONC212 for 2 weeks after ...
(A) Timeline of female C57BL/6 mice irradiated with a single whole-thorax dose of 20 Gy followed by treatment of either control gavage or 25 mg/kg of ONC212 (n = 8 per treatment per group). (Created in BioRender. Strandberg J. 2024. https://BioRender.com/z31h016.) (B) Weights of mice before radiation and 2 weeks after irradiation up until sacrifice at day 13 (n = 8 per treatment per group). (C) Kaplan-Meier curve of mice after 20 Gy thoracic irradiation treated with control gavage or 25 mg/kg of ONC212 (n = 8 mice per treatment per group). Mice were sacrificed before harvest date for greater than 20% weight loss. (D and E) Representative H&E images of cross section of distal esophagus of mice treated with control gavage or 25 mg/kg of ONC212 after 20 Gy thoracic irradiation at ×10 (D) and ×40 (E) original magnification. (F) Representative image of cross section of esophagus at ×10 original magnification highlighting tissue layers examined. (G and H) Quantification of thickness (μm) of different esophageal layers was determined by measurement of 5 random areas around the circumference of the esophagus for each mouse. There was a significant decrease in thickness of the muscularis externa (G) and muscularis mucosa (H) layers in mice treated with ONC212 (P = 0.0099, 0.0366, respectively). (I) Heatmap of cytokine fold change between control and ONC212-treated mice (n = 8 mice per treatment per group).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts